BACKGROUND: The prognostic significance of anti-53 autoantibody in colorectal cancer (CRC) patients is unclear due to measurement of overall rather than disease-specific survival and generally short follow-up periods in many studies. We aim to investigate prognostic significance of anti-p53 auto-antibodies in a study with long-term follow-up (minimum 5 years). METHODS: ELISA for anti-p53 autoantibody was assayed in serum from 92 patients with CRC and 28 controls. RESULTS: Anti-p53 autoantibody was found in 20 patients (21.7%) and none of the controls. No difference in Dukes' (A/B vs. C/D), Stage (I/II vs. III/IV), T1/2 vs. T3/4, N0 vs. N1/2, M0 vs. M1, poor vs. well/moderate differentiation and proximal vs. distal CRC was observed. Median overall survival was 62 months and median disease-specific survival was 73 months. Dukes' C/D, Stage III/IV, N1/2 and M1 were associated with poor disease-specific survival in univariate analysis. Stage III/IV was an independent prognostic factor in overall and disease-free survival in multivariate analysis. Anti-p53 autoantibody sero-positivity did not influence overall (p = 0.980) or disease-specific survival (p = 0.874). Median overall survival in anti-p53 autoantibody positive patients was 62 months vs. 60 months in anti-53 autoantibody negative patients. Median disease-specific survival in anti-p53 autoantibody positive patients was 73 months vs. 82 months. CONCLUSION: Anti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.
BACKGROUND: The prognostic significance of anti-53 autoantibody in colorectal cancer (CRC) patients is unclear due to measurement of overall rather than disease-specific survival and generally short follow-up periods in many studies. We aim to investigate prognostic significance of anti-p53 auto-antibodies in a study with long-term follow-up (minimum 5 years). METHODS: ELISA for anti-p53 autoantibody was assayed in serum from 92 patients with CRC and 28 controls. RESULTS: Anti-p53 autoantibody was found in 20 patients (21.7%) and none of the controls. No difference in Dukes' (A/B vs. C/D), Stage (I/II vs. III/IV), T1/2 vs. T3/4, N0 vs. N1/2, M0 vs. M1, poor vs. well/moderate differentiation and proximal vs. distal CRC was observed. Median overall survival was 62 months and median disease-specific survival was 73 months. Dukes' C/D, Stage III/IV, N1/2 and M1 were associated with poor disease-specific survival in univariate analysis. Stage III/IV was an independent prognostic factor in overall and disease-free survival in multivariate analysis. Anti-p53 autoantibody sero-positivity did not influence overall (p = 0.980) or disease-specific survival (p = 0.874). Median overall survival in anti-p53 autoantibody positive patients was 62 months vs. 60 months in anti-53 autoantibody negative patients. Median disease-specific survival in anti-p53 autoantibody positive patients was 73 months vs. 82 months. CONCLUSION: Anti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.
Authors: P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi Journal: Gut Date: 1997-03 Impact factor: 23.059
Authors: R Broll; M Duchrow; E Oevermann; C Wellm; O Schwandner; H Schimmelpenning; U J Roblick; H P Bruch; U Windhövel Journal: Int J Colorectal Dis Date: 2001-02 Impact factor: 2.571
Authors: R Tang; M C Ko; J Y Wang; C R Changchien; H H Chen; J S Chen; K C Hsu; J M Chiang; L L Hsieh Journal: Int J Cancer Date: 2001-12-15 Impact factor: 7.396
Authors: Y Y Juo; F M Johnston; D Y Zhang; H H Juo; H Wang; E P Pappou; T Yu; H Easwaran; S Baylin; M van Engeland; N Ahuja Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: J W Pedersen; A Gentry-Maharaj; E-O Fourkala; A Dawnay; M Burnell; A Zaikin; A E Pedersen; I Jacobs; U Menon; H H Wandall Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640